⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Efruxifermin (Efruxifermin) | 加速させる、線維化研究を

Home/Drugs/Efruxifermin

Efruxifermin

Efruxifermin

Phase 3

Sponsor: Akero Therapeutics

Indication: MASH

Mechanism of Action

FGF21 Analog

Target: FGF21

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

RECRUITINGNCT06528314

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Phase:PHASE3Org:Akero Therapeutics, Inc

COMPLETED

Relevant Publications (PubMed)

Untapped potential of efruxifermin in lean MASH.

Sotoudeheian M

Hepatol Int2025 Dec 1

Role of FGF21 in Heart Failure: Molecular Insights and Therapeutic Implications.

Agrawal SP, Tannous L, Tated RC et al.

Cardiol Rev2025 Nov 3

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

Browne SK, Suschak JJ, Tomah S et al.

JHEP Rep2025 Nov

Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review.

Validated Models

This drug has been validated in the following preclinical models:

NCT04767529

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase:PHASE2Org:Akero Therapeutics, Inc

RECRUITINGNCT06215716

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Phase:PHASE3Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT05039450

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Phase:PHASE2Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT06161571

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase:PHASE3Org:Akero Therapeutics, Inc

View all trials on ClinicalTrials.gov

Kamrul-Hasan ABM, Borozan S, Jena S et al.

World J Gastrointest Pharmacol Ther2025 Sep 5

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.

Noureddin M, Shringarpure R, Yale K

N Engl J Med2025 Sep 11

View more on PubMed